The effort was supported by other public interest groups and some Democratic members of Congress. U. C. L. A. made more than $500 million by selling its royalty rights to the drug. But the N. I. H. declined to exercise its   rights on Xtandi, arguing that it was not qualified to judge whether a drugâ€™s price is reasonable and that a high price does not mean a drug is not being made available to the public. " 